全文获取类型
收费全文 | 7018篇 |
免费 | 851篇 |
国内免费 | 3篇 |
出版年
2021年 | 107篇 |
2020年 | 59篇 |
2019年 | 81篇 |
2018年 | 68篇 |
2017年 | 78篇 |
2016年 | 153篇 |
2015年 | 274篇 |
2014年 | 282篇 |
2013年 | 334篇 |
2012年 | 487篇 |
2011年 | 503篇 |
2010年 | 272篇 |
2009年 | 279篇 |
2008年 | 411篇 |
2007年 | 450篇 |
2006年 | 394篇 |
2005年 | 436篇 |
2004年 | 403篇 |
2003年 | 424篇 |
2002年 | 384篇 |
2001年 | 81篇 |
2000年 | 55篇 |
1999年 | 97篇 |
1998年 | 111篇 |
1997年 | 78篇 |
1996年 | 77篇 |
1995年 | 74篇 |
1994年 | 84篇 |
1993年 | 71篇 |
1992年 | 59篇 |
1991年 | 61篇 |
1990年 | 54篇 |
1989年 | 49篇 |
1988年 | 48篇 |
1987年 | 65篇 |
1986年 | 39篇 |
1985年 | 51篇 |
1984年 | 64篇 |
1983年 | 56篇 |
1982年 | 86篇 |
1981年 | 57篇 |
1980年 | 55篇 |
1979年 | 47篇 |
1978年 | 34篇 |
1977年 | 43篇 |
1976年 | 27篇 |
1975年 | 28篇 |
1974年 | 20篇 |
1971年 | 18篇 |
1968年 | 18篇 |
排序方式: 共有7872条查询结果,搜索用时 15 毫秒
1.
Interleukin-1βconverting enzyme: A novel cysteine protease required for IL-1β production and implicated in programmed cell death 下载免费PDF全文
Nancy A. Thornberry Susan M. Molineaux 《Protein science : a publication of the Protein Society》1995,4(1):3-12
Interleukin-1β converting enzyme is the first member of a new class of cysteine proteases. The most distinguishing feature of this family is a nearly absolute specificity for cleavage at aspartic acid. This enzyme has been the subject of intense research because of its role in the production of IL-1β, a key mediator of inflammation. These studies have culminated in the design of potent inhibitors and determination of its crystal structure. The structure secures the relationship of the enzyme to CED-3, the product of a gene required for programmed cell death in Caenorhabditis elegans, suggesting that members of this family function in cell death in vertebrates. 相似文献
2.
3.
Elizabeth S. Browne Johnny R. Porter Gonzalo Correa Jude Abadie Frank Svec 《The Journal of steroid biochemistry and molecular biology》1993,45(6):517-524
Dehydroepiandrosterone (DHEA) decreases the activity of hepatic tyrosine aminotransferase (TAT), a glucocorticoid-inducible enzyme, in the obese, hypercorticosteronemic Zucker rat. To investigate the mechanism of this antiglucocorticoid action, the effect of exogenous DHEA on hepatic glucocorticoid receptor (GC) number and affinity was quantitated. Food supplementation with DHEA (0.6% w/w) for 1 or 7 days had no effect on either receptor number or affinity in obese Zucker rats. After 28 days, however, DHEA treatment resulted in a nearly 40% decrease in cytosolic hepatic receptor content (Bmax; fmol/mg cytosolic protein) without any change in affinity (Kd) in both lean and obese rats. DHEA treatment for 28 days also resulted in an increased liver size and cytosolic protein content. When the hepatic GC receptor content was normalized based on the change in liver size and protein content, the apparent number of GC binding sites per liver was not affected by DHEA treatment. This observation suggests that DHEA's effect on GC receptor content may not be a specific action and that downregulation of the GC receptor is not the mechanism of DHEA action on GC induced TAT activity. This is supported by the effect of DHEA on obese rat TAT activity in the same experiment where the greatest inhibition occurred after only 1 day of treatment. From these experiments it is concluded that although long-term DHEA treatment may decrease the relative concentration of GC receptors in rat liver, this change is not the mechanism through which DHEA mediates its acute antiglucocorticoid action. 相似文献
4.
Paul C. Marker Jennifer A. King Neal G. Copeland Nancy A. Jenkins David M. Kingsley 《Genomics》1995,28(3)
Murine Bmp7 has been assigned to distal Chromosome 2 by interspecific backcross mapping. The map location suggests close linkage to classical mouse mutations and places Bmp7 within a chromosome region thought to contain one or more unidentified imprinted genes. A direct test suggests that Bmp7 is not imprinted. An examination of embryonic RNA expression patterns shows that Bmp7 is expressed in a variety of skeletal and nonskeletal tissues. Both embryonic expression patterns and the human chromosomal sublocalization inferred from its mouse location make Bmp7 a candidate for the gene affected in some patients with Holt-Oram syndrome. 相似文献
5.
6.
7.
8.
9.
Emily Olfson Catherine E. Cottrell Nicholas O. Davidson Christina A. Gurnett Jonathan W. Heusel Nathan O. Stitziel Li-Shiun Chen Sarah Hartz Rakesh Nagarajan Nancy L. Saccone Laura J. Bierut 《PloS one》2015,10(9)
The American College of Medical Genetics and Genomics (ACMG) recommends that clinical sequencing laboratories return secondary findings in 56 genes associated with medically actionable conditions. Our goal was to apply a systematic, stringent approach consistent with clinical standards to estimate the prevalence of pathogenic variants associated with such conditions using a diverse sequencing reference sample. Candidate variants in the 56 ACMG genes were selected from Phase 1 of the 1000 Genomes dataset, which contains sequencing information on 1,092 unrelated individuals from across the world. These variants were filtered using the Human Gene Mutation Database (HGMD) Professional version and defined parameters, appraised through literature review, and examined by a clinical laboratory specialist and expert physician. Over 70,000 genetic variants were extracted from the 56 genes, and filtering identified 237 variants annotated as disease causing by HGMD Professional. Literature review and expert evaluation determined that 7 of these variants were pathogenic or likely pathogenic. Furthermore, 5 additional truncating variants not listed as disease causing in HGMD Professional were identified as likely pathogenic. These 12 secondary findings are associated with diseases that could inform medical follow-up, including cancer predisposition syndromes, cardiac conditions, and familial hypercholesterolemia. The majority of the identified medically actionable findings were in individuals from the European (5/379) and Americas (4/181) ancestry groups, with fewer findings in Asian (2/286) and African (1/246) ancestry groups. Our results suggest that medically relevant secondary findings can be identified in approximately 1% (12/1092) of individuals in a diverse reference sample. As clinical sequencing laboratories continue to implement the ACMG recommendations, our results highlight that at least a small number of potentially important secondary findings can be selected for return. Our results also confirm that understudied populations will not reap proportionate benefits of genomic medicine, highlighting the need for continued research efforts on genetic diseases in these populations. 相似文献
10.